LUPIN

shares rise on US launch of kidney drug Tolvaptan; $200 million revenue seen by FY26

The drug, a copy of Jynarque, could add up to $200 million in annual revenue by FY26, strengthening Lupin’s foothold in complex generics and supporting its margin recovery ***** of Lupin Ltd. edged 2.5 percent higher on Wednesday after the company announced the launch of Tolvaptan tablets in the US market, marking a key milestone in its US generics portfolio. The drug is a therapeutic equivalent of Jynarque, developed by Otsuka, and is used to treat autosomal dominant polycystic kidney disease (ADPKD) — a chronic condition with limited treatment ***** significance of this launch as a meaningful addition to Lupin’s US pipeline, with analysts estimating that the product could generate $200 million in annual revenues by FY26, assuming steady uptake and pricing stability. Jynarque is a relatively niche drug in the nephrology space but commands a strong pricing premium in the US market due to limited competition. Analysts believe the US generics opportunity remains a critical pillar in Lupin's recovery strategy, especially as the company focuses on complex products and specialty therapies to rebuild profitability. The launch also comes at a time when the Indian pharmaceutical industry is seeing a revival in US-bound product approvals and pricing stability after years of regulatory pressure and intense price erosion. This latest development follows a string of approvals Lupin has received from the USFDA in recent quarters, reinforcing its positioning in the complex generics segment. At last check, Lupin shares were trading higher on the NSE, extending recent gains fueled by a combination of steady earnings and strategic product launches in regulated markets.